A position... in what?? HALO, SGEN, CELG, TSLA, MUSA, OPK, ONVO and others... yeah... I post... I've got things to say when BCRX has things to say... compare me to Jacko on the number of posts???... the guy has to file a 13D every qtr with Yahoo... keep lobbin' em up...
"There have been 44 acquisitions of specialty drug companies for more than $500 million in the last three years, according to data compiled by Bloomberg. The average disclosed size was $1.2 billion and average premium was 20 percent, the data show. The largest deal was Perrigo Co. (PRGO)’s purchase of Elan Corp. for $6.2 billion earlier this year."
this one should be # 45 or 46.
a few more of you idiots go ahead and sell/short into this situation.. and get your head taken off:
4161 has DEMONSTRATED the potential to eliminate over 50% of HAE attacks. What's that worth?
Peramivir NDA could NOT be more timely. The world is awash in lethal flu virus.. and the company holds a nearly $300M inventory ofthe only IV flu treatment in the western world.. and could double with large orders for new production.
The 4208 gout/auto-immune molecule alone is worth twice the price of the stock.
Heck no Map... this guy has/will pumps the products waxing about "best-in-class", "dominate the space", "one pill once a day to wipe out attacks" and lets not forget non-dilutive offerings and Merck (which one) was impressed... shall I go on... I walk-the-walk every day... it's just on a different road with comments on the scenery...
The Ichan School of Medicine at Mount Saini has had their report published in Nature Communications. You can read the full report here.
The fact that the virus does not weaken once it develops resistance has caused grave concerns amongst scientists. The speed and virulence with which H7N9 strikes have had doctors worried since the disease first surfaced in China just a few months ago.
Although the disease has been proven to pass from person to person it does not at this point, do so easily. Scientists are concerned that should H7N9 infect a person who is suffering from seasonal, easily transmissible flu, that genetic reassortment will take place allowing the H7N9 virus to be easily passed from person to person.
And so the solution is just do nothing to prepare? I don't think so.
hey wood, how long has it been, officially on a MB, that you've admitted having a position?
and how many posts has it been since?
and you talk about jack...
"talking-the-talk" isn't that what you're doing? Sitting in a chair calling bad fouls on the ref? Isn't this what arm chair quarterbacks do, not players? Must be a real good lazy boy.
Plenty of stories of biotech that take time to get off the ground but when they do they shoot off like a rocket. If you don't think BCRX has the goods then put the remote down and place your bet.
I guess the Stoney buzz has changed from "best in class" to "dominate the space"... hey you might as well go for the homerun while you're JS'ing: "one tablet once a day to wipe out attacks"... geezus...
like an elephant in a phone booth:
two notorious virus strains, H1N1 and H7N9 are becoming resistant to Tamiflu.
so what will they use to treat high risk flu patients?
increasing dose of Tamiflu has no benefit even in non resistant virus,
I will start the "early treatment of influenza awareness campaign"
December 12, 2013
To start the "early treatment of influenza awareness campaign"
, We will carry out early treatment of influenza awareness campaign from Saturday December 14 ("Shionogi & Co., Ltd." Teshirogi Gong, following: Chuo-ku, Osaka, President Head Office) Shionogi & Co., Ltd..
Who as infants and the elderly pregnant women, those who or have underlying diseases such as diabetes and respiratory disease, when it is suffering from influenza, you may want to severe and complicated by pneumonia, and encephalopathy. Because there is a characteristic that either suppress the growth of the virus anti-influenza drug of existing, can not be fully effective in the administration after the severe virus can multiply, as soon as possible and seek medical attention influenza infection when suspected that is, to carry out early treatment by administration of anti-influenza drug is important.
In this campaign, the tail tree that was dressed as a friend role of mother to appoint Naoki place of education critic been popular since ages nicknamed "Oki mom" image character, are you active, with small children will be aired from Saturday, December 14, a new TV CM mom complain that "early treatment is important for influenza" is. In addition, it opened a web site in order to get a deeper understanding about the flu, we will continue to disseminate information.
The Shionogi & Co., Ltd., to our society in general, and to disseminate information on the importance of early treatment and a correct understanding about the flu, to patients of many, appropriate treatment with anti-influenza drug is made from the early even one person widely in the future By, so that leads to suppression of influenza severity of the public at large, we will strive.
[Influenza early treatment enlightenment summary of activities]
1. Television CM
To convey that early treatment is important, that there is a choice in the dosage form of the therapeutic agent, influenza will lead to a proper treatment promotion.
The request posted on the medical institutions across the country posters influenza early treatment awareness posters to 2. Medical institution, we aim to educate the patients.
Sentiment: Strong Buy
No mention of the gout space and RDEA's buyout??... the gout deal is now finally moot... did Stoney mention that one of the Mercks was impressed...
"Our goal is to dominate the space; ultimately with our program what we're hoping to have is the ability with one tablet once a day to wipe out attacks."
"And you're all probably aware that Shire recently offered $4.2 billion for the purchase of ViroPharma, so this is a highly valuable and lucrative space to be working in."
Don't sit around waiting too long to make an offer or the other guy will beat you to it.
His confidence on two fronts was apparent: IV P approval (likely) and Positive results with HAE and "dominating" the HAE niche.
I felt he wasn't talking to investors at the conferences, he was talking to potential suitors.
BioCryst Pharmaceuticals, Inc. (BCRX) Oppenheimer 24th Annual Healthcare Conference December 11, 2013 4:30 PM ET
Matt Lowe - Oppenheimer
We're going to keep things going here. Our next company to present is BioCryst Pharmaceuticals. Presenting on behalf of the company is going to be Jon Stonehouse. Jon is the President and CEO of the company. Jon?
Jon Stonehouse - Chief Executive Officer
Thank you, Matt. Thank you, Oppenheimer, for your invitation to your conference. I'm going to be making some forward-looking statements so statements have risks. Our risk factors can be found on our most recent filings on our website.
So, at the beginning of last year, we laid out a plan focused around three core assets. The first was to be a leader in the prophylactic treatment of hereditary angioedema with the first ever oral kallikrein inhibitors and we're fortunate to have BCX4161 that's entering the Phase II trial and a second generation program as well that I'll speak more about.
Our goal is to dominate the space; ultimately with our program what we're hoping to have is the ability with one tablet once a day to wipe out attacks. And so, it's a lofty goal but we think with a validated target and a small molecule, we have a very good shot at achieving that goal.
In addition to our HAE program, we also have two assets that are antivirals that I think the best way to describe to investors the value is non-dilutive financing, and let me say a little bit more about that.
With Peramivir, it's an IV neuraminidase similar to Tamiflu and Relenza, but will be used in very special cases, where oral and inhaled would not be appropriate and IV would be a better choice. And we're about to file an NDA. And so any dollar that comes from that program, whether it's seasonal sales or stockpiling will be a dollar that's not necessary to come from an investor to fund the HAE trial. So an unusual way of funding programs but one that we find to be a real upside for investors.
Sentiment: Strong Buy
I disagree with the Wooder that approval is already priced in. If there's one thiing that's clear, this puppy bounces on any and every little snippet. But I'm here for HAE. I hope some German dude is euphoric right now over how he feels.